{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T12:35:25Z","timestamp":1790253325265,"version":"4.1.0"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T00:00:00Z","timestamp":1764028800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T00:00:00Z","timestamp":1764028800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004435","name":"Universidad de Navarra","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004435","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hormones"],"published-print":{"date-parts":[[2026,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Anaplastic thyroid carcinoma (ATC) is a rare and highly aggressive malignancy historically associated with a poor prognosis and a median survival of only 3.16 months. However, recent advances in molecular profiling and immunotherapy are improving outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation<\/jats:title>\n                    <jats:p>We report the case of a 68-year-old man diagnosed with stage IVC ATC who achieved sustained disease stabilisation and long-term survival. Initial treatment with chemotherapy and radiotherapy led to partial remission of the primary tumour, although there was progression of metastatic disease. The patient was subsequently enrolled in a clinical trial investigating an anti-PD-L1 antibody with positive test results, followed by treatment with pembrolizumab. The latter resulted in nearly 11 years of disease control without significant adverse effects, an exceptional outcome in the context of ATC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This case underscores the transformative potential of immunotherapy in the management of advanced ATC and highlights the importance of continued research into combinatorial therapeutic strategies and predictive biomarkers to optimise treatment outcomes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s42000-025-00738-z","type":"journal-article","created":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T06:05:30Z","timestamp":1764050730000},"page":"267-271","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["A synergistic drug combination that aids our battle against anaplastic thyroid carcinoma: a case report and discussion"],"prefix":"10.1007","volume":"25","author":[{"given":"Estefan\u00eda","family":"Chumbiauca","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-9410-9351","authenticated-orcid":false,"given":"Isabela","family":"Vald\u00e9s Calero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 M.","family":"L\u00f3pez Picazo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Moreno-Jim\u00e9nez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allan","family":"Argueta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda D.","family":"Lozano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonidas","family":"Duntas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0227-3566","authenticated-orcid":false,"given":"Juan C.","family":"Galofr\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,25]]},"reference":[{"key":"738_CR1","volume-title":"The gates of fire: an epic novel of the battle of thermopylae","author":"S Pressfield","year":"2005","unstructured":"Pressfield S (2005) The gates of fire: an epic novel of the battle of thermopylae. Bantam Dell Pub Group, New York"},{"issue":"3","key":"738_CR2","doi-asserted-by":"publisher","first-page":"e15","DOI":"10.1016\/j.endonu.2014.11.006","volume":"62","author":"JM G\u00f3mez","year":"2015","unstructured":"G\u00f3mez JM, Jim\u00e9nez-Fonseca P, Santamar\u00eda J, Capdevila J, Navarro E, Zaf\u00f3n C et al (2015) Spanish consensus for the management of patients with anaplastic cell thyroid carcinoma. Endocrinol Nutr 62(3):e15\u201322. https:\/\/doi.org\/10.1016\/j.endonu.2014.11.006","journal-title":"Endocrinol Nutr"},{"issue":"9","key":"738_CR3","first-page":"5888","volume":"11","author":"B Lin","year":"2019","unstructured":"Lin B, Ma H, Ma M, Zhang Z, Sun Z, Hsieh IY et al (2019) The incidence and survival analysis for anaplastic thyroid cancer: a SEER database analysis. Am J Transl Res 11(9):5888\u20135896","journal-title":"Am J Transl Res"},{"issue":"9","key":"738_CR4","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1001\/jamaoncol.2020.3362","volume":"6","author":"A Maniakas","year":"2020","unstructured":"Maniakas A, Dadu R, Busaidy NL, Wang JR, Ferrarotto R, Lu C et al (2020) Evaluation of overall survival in patients with anaplastic thyroid carcinoma, 2000\u20132019. JAMA Oncol 6(9):1397\u20131404. https:\/\/doi.org\/10.1001\/jamaoncol.2020.3362","journal-title":"JAMA Oncol"},{"issue":"10","key":"738_CR5","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1089\/thy.2020.0086","volume":"30","author":"B Xu","year":"2020","unstructured":"Xu B, Fuchs T, Dogan S, Landa I, Katabi N, Fagin JA et al (2020) Dissecting anaplastic thyroid carcinoma: a comprehensive clinical, histologic, immunophenotypic, and molecular study of 360 cases. Thyroid 30(10):1505\u20131517. https:\/\/doi.org\/10.1089\/thy.2020.0086","journal-title":"Thyroid"},{"issue":"2","key":"738_CR6","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.endinu.2018.10.009","volume":"66","author":"JJ D\u00edez","year":"2019","unstructured":"D\u00edez JJ, Galofr\u00e9 JC, Oleaga A, Grande E, Mitjavila M, Moreno P (2019) Characteristics of professionalism of specialists and advantages of multidisciplinary teams in thyroid cancer: results of a National opinion survey. Endocrinol Diabetes Nutr (Engl Ed) 66(2):74\u201382. https:\/\/doi.org\/10.1016\/j.endinu.2018.10.009","journal-title":"Endocrinol Diabetes Nutr (Engl Ed)"},{"issue":"3","key":"738_CR7","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1089\/thy.2020.0944","volume":"31","author":"KC Bible","year":"2021","unstructured":"Bible KC, Kebebew E, Brierley J, Brito JP, Cabanillas ME, Clark TJ Jr et al (2021) American thyroid association guidelines for management of patients with anaplastic thyroid cancer. Thyroid 31(3):337\u2013386. https:\/\/doi.org\/10.1089\/thy.2020.0944","journal-title":"Thyroid"},{"issue":"8","key":"738_CR8","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1089\/thy.2019.0133","volume":"29","author":"JR Wang","year":"2019","unstructured":"Wang JR, Zafereo ME, Dadu R, Ferrarotto R, Busaidy NL, Lu C et al (2019) Complete surgical resection following neoadjuvant Dabrafenib plus Trametinib in BRAFV600E-Mutated anaplastic thyroid carcinoma. Thyroid 29(8):1036\u20131043. https:\/\/doi.org\/10.1089\/thy.2019.0133","journal-title":"Thyroid"},{"issue":"3","key":"738_CR9","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1089\/thy.2023.0573","volume":"34","author":"S Hamidi","year":"2024","unstructured":"Hamidi S, Iyer PC, Dadu R, Gule-Monroe MK, Maniakas A, Zafereo ME et al (2024) Checkpoint Inhibition in addition to dabrafenib\/trametinib for BRAFV600E-mutated anaplastic thyroid carcinoma. Hormones 34(3):336\u2013346. https:\/\/doi.org\/10.1089\/thy.2023.0573","journal-title":"Hormones"},{"issue":"1","key":"738_CR10","doi-asserted-by":"publisher","first-page":"553","DOI":"10.3892\/ol.2021.12814","volume":"22","author":"S Cameselle-Garc\u00eda","year":"2021","unstructured":"Cameselle-Garc\u00eda S, Abdulkader-Sande S, S\u00e1nchez-Ares M, Rodr\u00edguez-Carnero G, Garc\u00eda-G\u00f3mez J, Gude-Sampedro F et al (2021) PD-L1 expression and immune cells in anaplastic carcinoma and poorly differentiated carcinoma of the human thyroid gland: A retrospective study. Oncol Lett 22(1):553. https:\/\/doi.org\/10.3892\/ol.2021.12814","journal-title":"Oncol Lett"},{"issue":"1","key":"738_CR11","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/j.ecl.2018.10.010","volume":"48","author":"AV Chintakuntlawar","year":"2019","unstructured":"Chintakuntlawar AV, Foote RL, Kasperbauer JL, Bible KC (2019) Diagnosis and management of anaplastic thyroid cancer. Endocrinol Metab Clin North Am 48(1):269\u2013284. https:\/\/doi.org\/10.1016\/j.ecl.2018.10.010","journal-title":"Endocrinol Metab Clin North Am"},{"issue":"7","key":"738_CR12","doi-asserted-by":"publisher","first-page":"3527","DOI":"10.1007\/s00432-022-04223-7","volume":"149","author":"D Oliinyk","year":"2023","unstructured":"Oliinyk D, Augustin T, Rauch J, Koehler VF, Belka C, Spitzweg C, K\u00e4smann L (2023) Role of surgery to the primary tumor in metastatic anaplastic thyroid carcinoma: pooled analysis and SEER-based study. J Cancer Res Clin Oncol 149(7):3527\u20133547. https:\/\/doi.org\/10.1007\/s00432-022-04223-7","journal-title":"J Cancer Res Clin Oncol"},{"issue":"3","key":"738_CR13","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.amjoto.2017.02.005","volume":"38","author":"S Hu","year":"2017","unstructured":"Hu S, Helman SN, Hanly E, Likhterov I (2017) The role of surgery in anaplastic thyroid cancer: A systematic review. Am J Otolaryngol 38(3):337\u2013350. https:\/\/doi.org\/10.1016\/j.amjoto.2017.02.005","journal-title":"Am J Otolaryngol"},{"issue":"1","key":"738_CR14","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s13044-020-00091-w","volume":"13","author":"S De Leo","year":"2020","unstructured":"De Leo S, Trevisan M, Fugazzola L (2020) Recent advances in the management of anaplastic thyroid cancer. Thyroid Res 13(1):17. https:\/\/doi.org\/10.1186\/s13044-020-00091-w","journal-title":"Thyroid Res"},{"key":"738_CR15","unstructured":"U.S. Food and Drug Administration (FDA) (2022) FDA grants accelerated approval to dabrafenib in combination with trametinib for unresectable or metastatic solid tumors with BRAF V600E mutation. U.S. FDA. Accessed 29 Sept 2025 https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-dabrafenib-combination-trametinib-unresectable-or-metastatic-solid"},{"issue":"12","key":"738_CR16","doi-asserted-by":"publisher","first-page":"2168","DOI":"10.3390\/jcm8122168","volume":"8","author":"B Seliger","year":"2019","unstructured":"Seliger B (2019) Basis of PD1\/PD-L1 therapies. J Clin Med 8(12):2168. https:\/\/doi.org\/10.3390\/jcm8122168","journal-title":"J Clin Med"},{"issue":"s2","key":"738_CR17","doi-asserted-by":"publisher","first-page":"87","DOI":"10.3747\/co.27.5223","volume":"27","author":"K Esfahani","year":"2020","unstructured":"Esfahani K, Roudaia L, Buhlaiga N, Del Rincon SV, Papneja N, Miller WH (2020) A review of cancer immunotherapy: from the past, to the present, to the future. Curr Oncol 27(s2):87\u201397. https:\/\/doi.org\/10.3747\/co.27.5223","journal-title":"Curr Oncol"},{"issue":"3","key":"738_CR18","first-page":"974","volume":"12","author":"M Ma","year":"2020","unstructured":"Ma M, Lin B, Wang M, Liang X, Su L, Okose O et al (2020) Immunotherapy in anaplastic thyroid cancer. Am J Transl Res 12(3):974\u2013988","journal-title":"Am J Transl Res"},{"issue":"13","key":"738_CR19","doi-asserted-by":"publisher","first-page":"17194","DOI":"10.18632\/oncotarget.7839","volume":"7","author":"E Brauner","year":"2016","unstructured":"Brauner E, Gunda V, Vanden Borre P, Zurakowski D, Kim YS, Dennett KV et al (2016) Combining BRAF inhibitor and anti PD-L1 antibody dramatically improves tumor regression and anti-tumour immunity in an immunocompetent murine model of anaplastic thyroid cancer. Oncotarget 7(13):17194\u201317211. https:\/\/doi.org\/10.18632\/oncotarget.7839","journal-title":"Oncotarget"},{"issue":"7","key":"738_CR20","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1089\/thy.2020.0322","volume":"31","author":"C Dierks","year":"2021","unstructured":"Dierks C, Seufert J, Aumann K, Ruf J, Klein C, Kiefer S et al (2021) Combination of lenvatinib and pembrolizumab is an effective treatment option for anaplastic and poorly differentiated thyroid carcinoma. Thyroid 31(7):1076\u20131085. https:\/\/doi.org\/10.1089\/thy.2020.0322","journal-title":"Thyroid"},{"key":"738_CR21","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1186\/s12885-019-5380-3","volume":"19","author":"JM Mehnert","year":"2019","unstructured":"Mehnert JM, Varga A, Brose MS, Aggarwal R, Lin C, Prawira A et al (2019) Safety and antitumor activity of the anti\u2013PD-1 antibody pembrolizumab in patients with advanced, PD-L1\u2013positive papillary or follicular thyroid cancer (KEYNOTE-028). BMC Cancer 19:196. https:\/\/doi.org\/10.1186\/s12885-019-5380-3","journal-title":"BMC Cancer"}],"container-title":["Hormones"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s42000-025-00738-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s42000-025-00738-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s42000-025-00738-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T13:52:09Z","timestamp":1781617929000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s42000-025-00738-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,25]]},"references-count":21,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["738"],"URL":"https:\/\/doi.org\/10.1007\/s42000-025-00738-z","relation":{},"ISSN":["1109-3099","2520-8721"],"issn-type":[{"value":"1109-3099","type":"print"},{"value":"2520-8721","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,25]]},"assertion":[{"value":"30 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not required for a case report from our institution.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Written informed consent was obtained from the patient for the writing of this case report.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}